Perceptive Advisors LLC Boosts Stock Holdings in Nurix Therapeutics, Inc. $NRIX

Perceptive Advisors LLC boosted its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 151.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,555,877 shares of the company’s stock after purchasing an additional 2,139,728 shares during the period. Nurix Therapeutics comprises approximately 1.2% of Perceptive Advisors LLC’s portfolio, making the stock its 26th biggest holding. Perceptive Advisors LLC’s holdings in Nurix Therapeutics were worth $67,455,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of NRIX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Nurix Therapeutics by 11.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock valued at $593,000 after acquiring an additional 5,286 shares during the period. Millennium Management LLC raised its holdings in Nurix Therapeutics by 106.2% during the 1st quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after acquiring an additional 450,262 shares during the period. Goldman Sachs Group Inc. raised its holdings in Nurix Therapeutics by 9.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock valued at $6,029,000 after acquiring an additional 44,002 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Nurix Therapeutics by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock valued at $1,895,000 after acquiring an additional 12,817 shares during the period. Finally, Creative Planning bought a new stake in Nurix Therapeutics during the 2nd quarter valued at $187,000.

Wall Street Analyst Weigh In

NRIX has been the topic of a number of analyst reports. BTIG Research boosted their target price on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Jefferies Financial Group boosted their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 8th. Truist Financial boosted their target price on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, June 8th. Needham & Company LLC reissued a “buy” rating and set a $34.00 target price on shares of Nurix Therapeutics in a report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Nurix Therapeutics in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.14.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock opened at $17.12 on Thursday. The stock has a market cap of $1.77 billion, a P/E ratio of -5.42 and a beta of 1.86. Nurix Therapeutics, Inc. has a fifty-two week low of $8.19 and a fifty-two week high of $22.50. The firm’s fifty day moving average price is $16.51 and its 200-day moving average price is $16.91.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The firm had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million. Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.88 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Gwenn Hansen sold 3,214 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $16.65, for a total value of $53,513.10. Following the transaction, the insider owned 120,399 shares of the company’s stock, valued at $2,004,643.35. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares in the company, valued at approximately $624,027.20. This represents a 27.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 19,657 shares of company stock worth $326,586. 6.70% of the stock is owned by insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.